StageBio Director of Digital and Quantitative Pathology Thomas Lemarchand, DMV, DESV-AP, PhD, DECVP, recently co-authored a study that successfully demonstrated the effectiveness of a highly standardized porcine model for assessing dermal and epidermal wound healing.
Biotherapeutics like cell and gene therapies, nucleic acids, and proteins show promise for treating many neurodegenerative disorders.
While the Marburg virus disease (MVD) is deadly to humans, the filovirus responsible for it—i.e., the Marburg virus (MARV)—is carried asymptotically in Egyptian rousette bats (ERBs).
Toxicologic pathologists play a critical role in helping to determine the immunosafety of biopharmaceutical therapies.
Currently, healthy animal models play a critical role in the safety evaluation of a drug or health product. However, pharmaceutical companies and regulatory authorities are becoming increasingly interested in the use of animal models of disease (AMD) to better understand the potential risk of a diseased population. Recent publications and recommendations for the use of these models by regulators make the growing interest of the application of AMD highly evident.
What is self-amplifying mRNA technology? Self-amplifying mRNA (SAM) technology is a relatively novel approach in vaccinology. It consists of an engineered replication-deficient alphavirus genome encoding an RNA-dependent RNA polymerase and the gene of the target antigen. The benefit that SAM technology holds over conventional vaccinology is its potential for the rapid development and large-scale production of a vaccine in the event of an unpredictable epidemic outbreak.
513.204.4400
